NAMS
$30.45+0.66 (+2.22%)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
Recent News
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering
In February 2026, NewAmsterdam Pharma reported full-year 2025 sales of US$22.50 million and a net loss of US$203.82 million, while also filing an omnibus shelf registration to offer 5,719,966 common shares. At the same time, analysts highlighted management’s confidence in the late-stage obicetrapib program and a potentially accelerated European launch pathway, reinforcing interest in the company’s cardiovascular pipeline. We’ll now examine how management’s confidence in obicetrapib’s Phase...
NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit
NewAmsterdam Pharma (NASDAQ:NAMS) Chief Financial Officer Ian Somaiya said the company remains encouraged by early observations from its PREVAIL cardiovascular outcomes trial and reiterated plans to provide a mid-year update on study timelines during remarks at Guggenheim’s 2026 Emerging Outlook Bio
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility
NewAmsterdam Pharma (NAMS) is back on investors’ radar after recent trading left the stock at $31.86, with mixed short term returns and a much stronger 1 year and 3 year track record. See our latest analysis for NewAmsterdam Pharma. Recent trading has been choppy, with a 1 day share price return of a 2.54% decline and a 30 day share price return of a 14.47% decline. However, the 3 year total shareholder return of 222.8% points to momentum that has built over a longer horizon. If NewAmsterdam...
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, all asset classes except […]
Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally?
If you are wondering whether NewAmsterdam Pharma still offers good value after its big run, or if you are arriving too late to the party, you are in the right place to explore what the market might be missing. The stock is up 5.6% over the last week and 43.5% year to date, with a 50.9% gain over the past year suggesting that sentiment and expectations around the story have shifted significantly. Recent news flow has focused on NewAmsterdam Pharma's progress in late-stage clinical programs...